Exhibit 99.1 ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Preparing to submit response to the FDA’s CRL for neffy®(epinephrine nasal spray) in Type 1 allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen challenge study and nitrosamine assessments, with expected up to six-month review period In Phase 2 urticaria clinical trial, neffy met primary endpoints and showed rapid symptom control; plann ...